- /
- Supported exchanges
- / MX
- / GSKN.MX
GlaxoSmithKline plc (GSKN MX) stock market data APIs
GlaxoSmithKline plc Financial Data Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GlaxoSmithKline plc data using free add-ons & libraries
Get GlaxoSmithKline plc Fundamental Data
GlaxoSmithKline plc Fundamental data includes:
- Net Revenue: 32 780 M
- EBITDA: 11 433 M
- Earnings Per Share: 65
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-29
- EPS/Forecast: 1.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GlaxoSmithKline plc News
New
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, for the treatment of adults with refractory chronic cough (RCC). GSK was ev...
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in rectal cancer. The registrational phase II AZUR-1 study evaluated Jemper...
Connective Tissue Disease Associated with Interstitial Lung Disease Market Report, Details Drug Class Breakdown Across Corticosteroids, Antifibrotics, Immunosuppressants, and Biologics
Company Logo Connective tissue diseases (CTDs) associated with interstitial lung disease (ILD) involve autoimmune disorders affecting the skin, joints, and lungs, leading to inflammation and fibrosis...
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
Companies like Biogen and Royalty Pharma (Litifilimab), Biogen and UCB(Dapirolizumab pegol), Idorsia Pharmaceuticals and Viatris (Cenerimod), Novartis (Ianalumab, YTB3231), Kyowa Kirin (KK-4277), and ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.